Comparative Pharmacology
Head-to-head clinical analysis: MIRCETTE versus NORLESTRIN 28 1 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MIRCETTE versus NORLESTRIN 28 1 50.
MIRCETTE vs NORLESTRIN 28 1/50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol and desogestrel; estrogen and progestin inhibit gonadotropin release, suppressing ovulation and altering cervical mucus and endometrial receptivity.
Combination estrogen-progestin oral contraceptive; suppresses gonadotropin release via negative feedback on pituitary, inhibits ovulation, thickens cervical mucus, alters endometrial receptivity.
One tablet daily for 21 days, followed by 7 placebo tablets. Each active tablet contains 0.015 mg ethinyl estradiol and 2 mg chlormadinone acetate. Route: oral.
One tablet orally once daily, each containing norethindrone 1 mg and ethinyl estradiol 50 mcg.
None Documented
None Documented
Desogestrel active metabolite etonogestrel: 21-24 hours; ethinyl estradiol: 12-14 hours
Norethindrone: 8 hours; ethinyl estradiol: 12-15 hours; steady state achieved within 5-10 days.
Urine (50-60% as metabolites, <10% unchanged), feces (30-40% as metabolites)
Norethindrone: 40% renal, 60% fecal; ethinyl estradiol: 40% renal, 60% fecal.
Category C
Category C
Oral Contraceptive
Oral Contraceptive